Technology
Health
Biotechnology

Entasis Therapeutics

$6.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (0.61%) As of 2:57 PM EDT today
+$0.04 (0.61%) Today

Why Robinhood?

You can buy or sell ETTX and other stocks, options, ETFs, and crypto commission-free!

About ETTX

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. Read More The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. Entasis Therapeutics Holdings was founded in March 2018 and is headquartered in Waltham, MA.

Employees
33
Headquarters
Waltham, Massachusetts
Founded
2018
Market Cap
84.41M
Price-Earnings Ratio
Dividend Yield
Average Volume
5.16K
High Today
$6.35
Low Today
$6.33
Open Price
$6.35
Volume
5.65K
52 Week High
$13.70
52 Week Low
$3.97

Collections

Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Pharmaceutical
2018 IPO

ETTX Earnings

-$20.00
-$13.60
-$7.20
-$0.80
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 14, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.